Monopar Therapeutics Inc. Current Liabilities
Monopar Therapeutics Inc. (MNPR) had Current Liabilities of $4.02 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Liabilities, Current $4.02M.
- 2026-03-31: Liabilities, Current $2.46M.
- 2025-12-31: Liabilities, Current $2.74M.
- 2025-09-30: Liabilities, Current $2.57M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $4.02M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $2.46M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $2.74M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $2.57M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.58M 10-Q · filed 2025-08-12 |
| 2024-12-31 | $5.25M 10-K · filed 2026-03-27 |
| 2023-12-31 | $1.76M 10-K · filed 2024-03-28 |
| 2023-09-30 | $1.98M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $2.50M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $2.89M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $3.13M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.91M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $2.19M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $1.07M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.58M 10-K · filed 2023-03-23 |
| 2021-03-31 | $806.27K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $1.18M 10-Q · filed 2021-05-13 |
| 2020-09-30 | $609.84K 10-Q · filed 2020-11-12 |
| 2020-06-30 | $573.13K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $443.52K 10-Q · filed 2020-05-07 |
| 2019-12-31 | $724.16K 10-K · filed 2021-03-25 |
| 2019-09-30 | $483.67K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $468.27K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $579.99K 10-Q · filed 2019-05-10 |
| 2018-12-31 | $399.55K 10-K · filed 2020-03-27 |
| 2018-09-30 | $311.89K 10-Q · filed 2018-11-09 |
| 2018-06-30 | $323.06K 10-Q · filed 2018-08-09 |
| 2018-03-31 | $290.60K 10-Q · filed 2018-05-11 |
| 2017-12-31 | $311.87K 10-K · filed 2019-02-26 |
| 2016-12-31 | $64.51K 10-K · filed 2018-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |